IP Library › Granted Patent US 9,428,552
Granted Patent B2
US 9,428,552 · App. 14/442,737 · Granted Aug 30, 2016

Stem cell mobilization and tissue repair and regeneration

Inventors: Irena Tsyrlova (Bethesda, MD); Fawn Petty (Bowie, MD); Reid W. von Borstel (Potomac, MD); Julian Reading (Frederick, MD); Jiong Pei (Dobbs Ferry, NY); Joel Saydoff (Frederick, MD)
Assignee: Wellstat Therapeutics Corporation
C07K7/08A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,428,552
App. No.
14/442,737
Granted
Aug 30, 2016
Kind
B2
Abstract

Stem cells are mobilized from bone marrow by administering an amount of Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2) or Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3) effective to mobilize the stem cells. This is useful for promoting bodily tissue regeneration in a patient in need of tissue regeneration treatment. Alternatively, the mobilized stem cells can be collected for transplant.

Claims (18)

1. An oligopeptide having the sequence Phe-Xaa-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 1), wherein Xaa is Pro or Ala.

2. The oligopeptide of claim 1 having the sequence Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2).

3. The oligopeptide of claim 1 having the sequence Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3).

4. A pharmaceutical composition comprising a compound (SEQ ID NO: 1) for mobilizing stem cells from bone marrow of a subject.

5. A method of mobilizing stem cells from bone marrow of a subject, comprising administering to the subject an amount of compound (SEQ ID NO: 1) effective to mobilize the stem cells.

6. The method of claim 5 , wherein the subject is a human and the amount of (SEQ ID NO: 1) is from 100 micrograms to 10 milligrams per administration, administered from 1 time per week to 3 times per day.

7. A method for treating a subject in need of one or more of preservation, repair, or regeneration of bodily tissue, or revascularization, comprising the method of claim 5 , thereby promoting the one or more of preservation, repair, or regeneration of bodily tissue or regeneration in the subject.

8. A method for treating a subject in need of one or more of preservation, repair, or regeneration of bodily tissue, or revascularization, comprising the method of claim 6 , thereby promoting the one or more of preservation, repair, or regeneration of bodily tissue or regeneration in the subject.

9. The method of claim 7 , wherein the tissue that is preserved, repaired or regenerated is pancreatic tissue.

10. A method of treating diabetes comprising the method of claim 9 .

11. The method of claim 8 , wherein the tissue that is preserved, repaired or regenerated is pancreatic tissue.

12. A method for treating diabetes comprising the method of claim 11 .

13. The method of claim 7 , wherein the tissue that is preserved, repaired, or regenerated is dermal tissue.

14. A method for treating a dermal wound, comprising the method of claim 13 .

15. The method of claim 8 , wherein the tissue that is preserved, repaired, or regenerated is dermal tissue.

16. A method of treating a dermal wound, comprising the method of claim 15 .

17. The method according to claim 5 , wherein the compound has the sequence Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 2).

18. The method according to claim 5 , wherein the compound has the sequence Phe-Ala-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gln-Val-Ser-Asp-Lys-Pro (SEQ ID NO: 3).

Continuity (3)
Provisional Application 61735227 · Dec 10, 2012
Provisional Application 61728058 · Nov 19, 2012
Related Publication 20160016997A1 · Jan 21, 2016